By a Staff Reporter: Aurobindo Pharma: Board OKs 1.50 rupees/share interim dividend
Aurobindo Pharma: Jul-Sep consol net profit 6.9 bln rupees vs 8.1 bln
Analysts estimated Aurobindo Pharma Jul-Sep consol PAT 7.7 bln rupees
Aurobindo Pharma: Jul-Sep consol revenue 59.4 bln rupees vs 64.8 bln
Aurobindo Pharma:Panel to consider restructuring of arm Eugia Pharma
Aurobindo Pharma: Jul-Sep consol EBITDA margin 20% vs 21.3% year ago
Aurobindo Pharma: Jul-Sep US sales at 29.7 bln rupees, up 7% on yr
Aurobindo Pharma: Jul-Sep Europe sales 16.6 bln rupees, up 10% YoY
Aurobindo Pharma: Jul-Sep R&D spend 3.99 bln rupees, 6.7% of sales
Source : Eureka
Please register at https://kyc.eurekasecurities.net/home/index/729 for opening Trading and Demat Account.